Skip to main content

Table 3 Cox regression models using recurrence-free survival as the main outcome of interest after backward selection

From: MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival

 

Covariate: BPE

Covariate: BPE (limited subset)

Covariate: FGT

Covariate: breast density

Log (HR)

p value

Log (HR)

p value

Log (HR)

p value

Log (HR)

p value

Hormonal treatment duration

 1–5 years

1.52

< .0001

1.52

< .0001

1.61

< .0001

3.17

0.02

 ≥ 6 years

Ref

 

Ref

 

Ref

 

Ref

 

Number of metastatic lymph nodes

 > 3

2.49

< .0001

1.86

< 0.001

2.64

< .0001

3.11

0.001

 Micro to 3

0.62

0.08

0.44

0.29

0.79

0.03

1.52

0.06

 Non-metastatic

Ref

 

Ref

 

Ref

 

Ref

 

Diameter

 20–49 mm

  

− 0.62

0.28

    

 > 50 mm

  

1.16

0.03

    

 Micro to 19 mm

  

Ref

     
  1. Limited subset: Only individuals with mild/moderate/significant parenchymal enhancement were included in the limited subset analysis
  2. Abbreviations: BPE background parenchymal enhancement, FGT fibroglandular tissue, HR hazard ratio